Mulé S J, Casella G, Clouet D H
Psychopharmacologia. 1975 Oct 31;44(2):125-9. doi: 10.1007/BF00420998.
When 3H-etorphine was administered to rats in a pharmacologically effective dose (0.75 mug/kg intracisternally), the labeled drug was concentrated in synaptic membrane fractions isolated from the brains of rats killed 10 min after etorphine injection. Pretreatment of the animals with the narcotic antagonists naloxone, diprenorphine or l-cyclorphan, blocked the pharmacological responses to etorphine and reduced 3H-etorphine binding in the membrane fractions. The differences between 3H-etorphine bound in synaptic membranes of rats treated with d-cyclorphan (inactive isomer) and l-cyclorphan (active antagonist) were in the same range as the reductions in etorphine binding in antagonist-treated rats, indicating that stereospecific and pharmacologically-specific binding sites in synaptic membranes in vivo were of the same magnitude: about 0.04 pmol/g brain.
当以药理有效剂量(脑池内注射0.75微克/千克)给大鼠施用3H-埃托啡时,标记药物集中在从埃托啡注射10分钟后处死的大鼠脑中分离出的突触膜组分中。用麻醉拮抗剂纳洛酮、二丙诺啡或l-环丙啡对动物进行预处理,可阻断对埃托啡的药理反应,并减少膜组分中3H-埃托啡的结合。用d-环丙啡(无活性异构体)和l-环丙啡(活性拮抗剂)处理的大鼠突触膜中结合的3H-埃托啡之间的差异,与拮抗剂处理的大鼠中埃托啡结合减少的范围相同,表明体内突触膜中的立体特异性和药理特异性结合位点大小相同:约0.04皮摩尔/克脑。